If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
67
results.
Updated on
14/07/2026 [07:40:00]
Results 50 to 67 of 67
Absstract of: AU2024409393A1
The present disclosure provides a method for delivering a nucleic acid cargo to the liver of a subject, the method comprising administering to the subject a lipid nanoparticle encapsulating the nucleic acid and comprising a non-polar lipid. The lipid nanoparticle may exhibit a blebbed morphology, despite the absence or low levels of phospholipid. The disclosure further provides compositions for delivering nucleic acid cargo to the liver in order to treat various diseases, disorders and conditions in the subject.
Absstract of: AU2024406406A1
The present disclosure provides nitrogen-containing silicon ether ionizable lipid compounds and lipid nanoparticles including the ionizable lipid. The disclosure further relates to lipid nanoparticles including a provided ionizable lipid compound together with a phospholipid, e.g., a phospholipid that includes at least one unsaturated tail and a head group having a positively charged nitrogen. The provided materials are particularly beneficial in applications involving delivery of a nucleic acid. The disclosure also provides pharmaceutical compositions and methods including the provided ionizable lipids and/or lipid nanoparticles.
Absstract of: US20260191797A1
0000 The present invention relates to the field of polymer chemistry and more particularly to poly(amino acid) copolymers and uses thereof for drug delivery applications. In particular, the present invention concerns a linear copolymer comprising a polysarcosine block, pSar, containing from 15 to 99 sarcosine constitutional units and a poly(amino acid) block, pAA, containing from 8 to 120 amino acid constitutional units.
Absstract of: US20260191989A1
0000 Presented herein are compositions and methods for gene therapy.
Absstract of: US20260191987A1
The present invention relates to a gene carrier including a nucleic acid molecule containing a gene of interest conjugated to the surface of a metal nanoparticle, which is delivered into cells and expressed, a use thereof, a gene expression method using the same, and a method of preparing the same.
Absstract of: US20260193647A1
0000 A nanomedicine platform that involves the use of a blood brain-permeable tumor-navigating probe that includes a peptide p28 covalently linked with antisense miRNA. The probe localized in intracerebral human pediatric glioblastoma tumors in mice. Upon cellular entry, the probe significantly inhibits tumor cell viability by silencing the oncogenic miRNA miR-20a. Notably, systemic administration of the probe enabled complete regression of the ear-ly-stage tumor and significantly prolonged overall survival without apparent adverse effects.
Absstract of: AU2024397320A1
Compositions and methods for treating a cancer or an infectious disease by delivering a compound comprising a polymeric backbone and a STING agonist covalently linked by a stimulus responsive linker are provided.
Absstract of: AU2024385239A1
The present disclosure relates to lipids and compositions thereof. In various aspects of the invention, the compositions are lipid nanoparticle compositions used to deliver various DNA molecules and/or therapeutic agents to selected targets, such as cells for gene delivery, and/or to prevent or treat diseases or disorders in a subject in need thereof.
Absstract of: AU2024384650A1
Provided herein are emulsion composition comprising a medium chain triglyceride (MCT), preferably tricaprilin. Also, described here are additional ingredients that make these emulsion compositions more suitable for oral intake, such as one or more emulsifiers, buffers such as phosphate buffers, as well as optionally glycerol and a sweetener and/or a flavoring agent. Described herein are methods of making and using these emulsions. The emulsions described may be used for oral administration of tricaprilin to treat and/or prevent various diseases or disorders.
Absstract of: US20260191997A1
The present disclosure provides conjugates that comprise a small molecule attached to an antifouling nanoparticle. The present disclosure also provides methods of using such conjugates, such as diagnosis, tissue imaging, temporal monitoring, and treatment.
Absstract of: US20260191796A1
0000 Disclosed herein are methods of increasing the potency of nucleic acid loaded lipid nanoparticles (naLNPs) through certain novel and surprisingly superior LNP manufacturing techniques. Also disclosed are pharmaceutical compositions containing naLNPs manufactured according to the manufacturing methods described herein. The methods disclosed herein overcome major technical difficulties and high costs associated with previous LNP manufacturing techniques. The methods disclosed herein, therefore, greatly improve the industrial production of LNPs in unexpected ways thereby providing more potent naLNPs for nucleic acid delivery. Specifically, the invention disclosed herein are methods that show increased potency naLNPs due to increased mixing concentration of the lipids and mRNA during assembly.
Absstract of: AU2024390885A1
The present invention provides a composite molecule, a nucleic acid, a vector, a host cell, and a pharmaceutical composition, and uses of the composite molecule, the nucleic acid, the vector, the host cell, and the pharmaceutical composition in preparation of drugs for treating cancers. The composite molecule comprises an anti-tumor antibody domain, a linker, and pro-IL-15; the anti-tumor antibody domain is linked to the pro-IL-15 by means of the linker; the anti-tumor antibody domain is a complete antibody against an immune checkpoint molecule, a tumor antigen molecule or an immune activation molecule, or a nano antibody or an antigen binding fragment thereof; the linker is a polypeptide linker or a non-peptide linker; the pro-IL-15 is a fusion protein comprising IL-15, an IL-15Rα sushi domain, and a linker peptide, and optionally comprising an IL-15Rβ extracellular domain; and the IL-15Rβ extracellular domain, the IL-15, and the IL-15Rα sushi domain are linked by means of the linker peptide.
Absstract of: US20260191895A1
0000 A method of treating a patient with a tumor, comprising administering, to the patient, a substance which activates cytoplasmatic sensors for intracellular pathogen in the tumor, in one or more doses; and treating the tumor with intra-tumoral alpha-emitter radiotherapy within two weeks of administering the substance which activates cytoplasmatic sensors for intracellular pathogen in the tumor, and at least 12 hours after administering the substance. The substance is selected from the group of a DNA methyltransferase (DNMT) inhibitor, and a histone deacetylase (HDAC) inhibitor.
Absstract of: US20260191791A1
The present invention provides stable, dry powder messenger RNA formulations for therapeutic use, and methods of making and using the same.
Absstract of: WO2026144775A1
The present invention relates to the technical field of biomedicine. The present invention aims to provide a use of Mn3O4 nanoparticles in alleviating intervertebral disc degeneration, trimanganese tetroxide nanoparticles Mn3O4 NPs are added as nanozymes to interventional drugs for treating intervertebral disc degeneration. The present invention uses Mn3O4 nanoparticles as nano-active catalytic enzymes, which have multi-enzyme catalytic activities similar to superoxide dismutase, catalase, and glutathione peroxidase, and can effectively scavenge reactive oxygen species (ROS) and control ECM metabolism, significantly reducing cell apoptosis, delaying cell senescence, inhibiting inflammation, and enhancing autophagy, thereby promoting annulus fibrosus AF repair in the treatment of intervertebral disc degeneration. Mn3O4 nanoparticles have good biocompatibility, and metabolites thereof can be used in other physiological processes, producing no toxic side effects in the in vivo circulation. Furthermore said nanoparticles perform stably in adverse microenvironments of low oxygen and low pH in intervertebral discs, and have in vivo stability that other active catalytic enzymes do not possess.
Absstract of: US20260191783A1
The disclosure provides drug delivery formulations that comprise a porous silicon material and a meltable compound, such as a progestin drug, or a meltable composition. The formulations provide for the controlled release of the progestin drug, or other therapeutic agent, over long time periods. In some embodiments, the meltable composition further comprises a melting point suppression agent, where the melting point suppression agent enables the loading of thermally unstable therapeutic agents into the porous silicon material by melt casting that would not otherwise be possible absent the melting point suppression agent. The disclosure additionally provides methods of making and using the drug delivery formulations.
Absstract of: US20260191951A1
The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
Absstract of: WO2026145606A1
Disclosed are a UTR element and a use thereof. The UTR element is selected from a 3'UTR sequence as shown in SEQ ID NO: 7 or 8. The UTR element can prolong the expression and stability of mRNA and significantly improve the immune effect of a vaccine.
Absstract of: WO2026145605A1
Disclosed are a 5' UTR and the use thereof. The 5' UTR has a nucleotide sequence selected from a sequence as shown in any one of SEQ ID NOs: 1-6. The 5' UTR can prolong the expression and stability of an mRNA, and significantly improve the immune effect of a vaccine.
Absstract of: US20260191994A1
Lipid nanoparticles are used to deliver various types of nuclei acids to different tissues in vivo, providing a novel tool for gene editing.
Absstract of: WO2026147476A1
This invention relates to the development of a biodegradable scaffold containing growth factor and antibiotic loaded nanoparticulate systems with the aim of enabling the regeneration of the pulp-dentin complex of immature permanent teeth with necrotic pulp damaged due to infection, trauma, or developmental anomalies.
Absstract of: US20260193374A1
The present invention is directed to bispecific Her-2-CD3 epsilon (CD3e) antigen-binding molecules. The present invention is further directed to a method for treating Her-2-positive cancer cells by administering the bispecific Her-2-CD3e antigen-binding molecule to the tumors. This invention provides a method of antibody production in cells and inside tumors with high in vivo efficacy through intratumoral delivery of mRNA encapsulated-lipid nanoparticles, wherein the mRNA encodes the antibody.
Absstract of: WO2026145679A1
A carrier-drug conjugate, and a preparation method therefor and a use thereof, relating to the technical fields of biomedical technology, nanomedicine, and drug delivery. The carrier-drug conjugate is a non-absorbable carrier-drug conjugate, comprising a non-absorbable carrier unit, a linker, and a receptor binding agent unit. The non-absorbable carrier-drug conjugate exhibits a variation in hydrodynamic diameter of no more than 5% within 24 hours in a gastrointestinal tract physiological environment, and the proportion absorbed within 24 hours in the gastrointestinal tract physiological environment does not exceed 1%. When the non-absorbable carrier-drug conjugate is administered via a gastrointestinal tract, the non-absorbable carrier-drug conjugate remains stable in a gastrointestinal tract environment and is not absorbed by the gastrointestinal tract into systemic circulation. Therefore, the non-absorbable carrier-drug conjugate can specifically bind to targets on the surface of gastrointestinal tract cells, overcoming the limitations of conventional drug administration where drugs act on targets throughout a body, and reducing side effects.
Absstract of: US20260191799A1
The present disclosure relates to polymer nanoparticles of metabolites, a cell activity promotion method using same, and a cell activity promotion composition including same. In particular, the present disclosure relates to a method and a composition, for promoting, by the permeation of polymer nanoparticles of metabolites into cells, the activities of cells, for example, adhesion between cells or between tissues, hemostasis, wound healing promotion, hair root regeneration activity, and antibacterial activity.
Nº publicación: WO2026146172A1 09/07/2026
Applicant:
GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC [CA]
GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD [GB]
GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC
GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LIMITED
Absstract of: WO2026146172A1
The disclosure features a method of lyophilizing lipid nanoparticles including mixing a lyophilization buffer with a lipid nanoparticle formulation to form a lyophilization formulation and lyophilizing the lyophilization formulation to form lyophilized lipid nanoparticles, where the method is free of a buffer exchange process.
BOPI
Electronic site
